Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Inkwood Research | PRODUCT CODE: 1069198

Cover Image

PUBLISHER: Inkwood Research | PRODUCT CODE: 1069198

Asia-pacific Drug Discovery Market Forecast 2022-2030

PUBLISHED:
PAGES: 165 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 1600
PDF (Corporate License)
USD 2200

Add to Cart

KEY FINDINGS

The Asia-Pacific drug discovery market is predicted to register a CAGR of 7.13% during the forecast period, 2022-2030. The existing healthcare challenges and the dense population base offer lucrative research and clinical trials opportunities for pharmaceuticals and CROs.

MARKET INSIGHTS

Taiwan, Japan, Australia & New Zealand, India, Singapore, Indonesia, South Korea, China, and Rest of Asia-Pacific are analyzed for the Asia-Pacific drug discovery market growth evaluation. In Japan, product initiatives and launches contribute to market growth. For instance, the Pharmaceuticals and Medical Devices Agency is a regulatory agency that collaborates with the Ministry of Health, Labour and Welfare to protect public health by assuring the quality, efficacy, and safety of medical and pharmaceuticals. Also, the Tokyo Medical and Dental University announced a technology that uses AI (artificial intelligence) for discovering drug resistance's new casual mechanisms in cancer treatments from clinical data.

India has a strong foothold and drug manufacturing capacities in generic drugs production and sales. Several industry experts of prominent Indian pharma companies are prioritizing novel drug discovery and development. Also, the industry leaders are modernizing, enhancing, and developing their R&D capabilities. In addition, the Drugs Controller General of India (DCGI) regulates the imports and sales of drugs for clinical trial use and permits clinical trials. Further, the government introduced the country's first-ever national initiative for supplementing the drug discovery process in July 2020.

In Indonesia, the NA-DFC (National Agency of Drug and Food Control) ensures the efficacy, quality, and safety of pharmaceuticals in Indonesia. It grants drug approvals in the form of a marketing authorization license and oversees the drug registration application review process. Such factors drive market growth in these countries.

COMPETITIVE INSIGHTS

Some of the eminent companies in the market include: AstraZeneca Plc, Charles River, Laboratories International Inc, Bayer AG, Eli Lilly and Company, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 13801

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
    • 3.1.2. TECHNOLOGICAL ADVANCEMENTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
    • 3.2.2. HIGHLY REGULATED MARKET
    • 3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
    • 4.5.1. DRUG DISCOVERY AND DEVELOPMENT
    • 4.5.2. PRECLINICAL RESEARCH
    • 4.5.3. CLINICAL RESEARCH
    • 4.5.4. REGULATORY AUTHORITY REVIEW
    • 4.5.5. POST MARKET SAFETY MONITORING
  • 4.6. REGULATORY FRAMEWORK

5. MARKET BY DRUG TYPE

  • 5.1. SMALL MOLECULE DRUG
  • 5.2. BIOLOGIC DRUG

6. MARKET BY SERVICE

  • 6.1. CHEMICAL SERVICES
  • 6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
  • 6.3. BIOLOGICAL SERVICES
  • 6.4. OTHER PHARMACEUTICAL SERVICES

7. MARKET BY END-USER

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT RESEARCH ORGANIZATIONS
  • 7.3. RESEARCH INSTITUTES
  • 7.4. OTHER END-USERS

8. MARKET BY TECHNOLOGY

  • 8.1. HIGH THROUGHPUT SCREENING
  • 8.2. SPECTROSCOPY
  • 8.3. COMBINATORIAL CHEMISTRY
  • 8.4. BIOCHIPS
  • 8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 8.6. BIOINFORMATICS
  • 8.7. METABOLOMICS
  • 8.8. NANOTECHNOLOGY
  • 8.9. OTHER TECHNOLOGIES

9. GEOGRAPHICAL ANALYSIS

  • 9.1. ASIA-PACIFIC
    • 9.1.1. MARKET SIZE & ESTIMATES
    • 9.1.2. KEY GROWTH ENABLERS
    • 9.1.3. KEY CHALLENGES
    • 9.1.4. KEY PLAYERS
    • 9.1.5. COUNTRY ANALYSIS
      • 9.1.5.1. CHINA
      • 9.1.5.2. JAPAN
      • 9.1.5.3. INDIA
      • 9.1.5.4. SOUTH KOREA
      • 9.1.5.5. INDONESIA
      • 9.1.5.6. SINGAPORE
      • 9.1.5.7. TAIWAN
      • 9.1.5.8. AUSTRALIA & NEW ZEALAND
      • 9.1.5.9. REST OF ASIA-PACIFIC

10. COMPETITIVE LANDSCAPE

  • 10.1. KEY STRATEGIC DEVELOPMENTS
    • 10.1.1. MERGERS & ACQUISITIONS
    • 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 10.1.3. PARTNERSHIPS & AGREEMENTS
    • 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 10.2. COMPANY PROFILES
    • 10.2.1. AGILENT TECHNOLOGIES INC
    • 10.2.2. ASTRAZENECA PLC
    • 10.2.3. BAYER AG
    • 10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
    • 10.2.5. ELI LILLY AND COMPANY
    • 10.2.6. EVOTEC SE
    • 10.2.7. GLAXOSMITHKLINE PLC
    • 10.2.8. ICON PLC
    • 10.2.9. IQVIA HOLDINGS INC
    • 10.2.10. JOHNSON & JOHNSON
    • 10.2.11. MERCK & CO INC
    • 10.2.12. NOVARTIS AG
    • 10.2.13. PFIZER INC
    • 10.2.14. ROCHE AG
Product Code: 13801

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ASIA DRUG DISCOVERY
  • TABLE 2: REGULATORY FRAMEWORK
  • TABLE 3: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 4: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 11: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 12: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 13: LEADING PLAYERS OPERATING IN ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET
  • TABLE 14: LIST OF MERGERS & ACQUISITIONS
  • TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • FIGURE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
  • FIGURE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
  • FIGURE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 11: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 12: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 13: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
  • FIGURE 14: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
  • FIGURE 15: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
  • FIGURE 16: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
  • FIGURE 17: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
  • FIGURE 18: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
  • FIGURE 19: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
  • FIGURE 20: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
  • FIGURE 21: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
  • FIGURE 22: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
  • FIGURE 23: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
  • FIGURE 24: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
  • FIGURE 25: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
  • FIGURE 26: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
  • FIGURE 28: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 29: CHINA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 30: JAPAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: INDIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 32: SOUTH KOREA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 33: INDONESIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 34: SINGAPORE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 35: TAIWAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 36: AUSTRALIA & NEW ZEALAND DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 37: REST OF ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!